Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Cartron G, Chaillol I, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, La Rochelle LD, Feugier P, Marcais A, Ould-Ammar R, Tarte K, Laurent C, Sesques P

Open source

DOI: 10.1186/s13045-026-01816-4
Published: 2026 Jul 1
Container: Journal of hematology & oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13045-026-01816-4,
  title = {Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.},
  author = {Cartron G and Chaillol I and Houot R and Al Tabaa Y and Le Bras F and Ysebaert L and Choquet S and Jardin F and Bay JO and Gros FX and Morschhauser F and Rossi C and Gastinne T and Thieblemont C and Joris M and Ricard L and Regny C and La Rochelle LD and Feugier P and Marcais A and Ould-Ammar R and Tarte K and Laurent C and Sesques P},
  year = {2026},
  journal = {Journal of hematology \& oncology},
  doi = {10.1186/s13045-026-01816-4},
  url = {https://doi.org/10.1186/s13045-026-01816-4}
}

RIS

TY  - JOUR
TI  - Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.
AU  - Cartron G
AU  - Chaillol I
AU  - Houot R
AU  - Al Tabaa Y
AU  - Le Bras F
AU  - Ysebaert L
AU  - Choquet S
AU  - Jardin F
AU  - Bay JO
AU  - Gros FX
AU  - Morschhauser F
AU  - Rossi C
AU  - Gastinne T
AU  - Thieblemont C
AU  - Joris M
AU  - Ricard L
AU  - Regny C
AU  - La Rochelle LD
AU  - Feugier P
AU  - Marcais A
AU  - Ould-Ammar R
AU  - Tarte K
AU  - Laurent C
AU  - Sesques P
PY  - 2026
JO  - Journal of hematology & oncology
DO  - 10.1186/s13045-026-01816-4
UR  - https://doi.org/10.1186/s13045-026-01816-4
ER  -

APA

G, C., I, C., R, H., Y, A. T., F, L. B., L, Y., S, C., F, J., JO, B., FX, G., F, M., C, R., T, G., C, T., M, J., L, R., C, R., LD, L. R., P, F., A, M., R, O., K, T., C, L., & P, S. (2026). Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.. Journal of hematology & oncology. https://doi.org/10.1186/s13045-026-01816-4

Source records

pubmed · retrieved 2026-09-27T09:28:17.686Z